ATHE
Alterity Therapeutics Limited
NASDAQ · Healthcare · Biotechnology · AU
$4.54
+0.44%Aug 12, 2026, 11:05 UTC
Alterity Therapeutics announced the granting of a new U.S. composition of matter patent for its drug candidate ATH434, extending protection to at least 2045.
Source:Jul 7, 2026, 11:05 UTC
Alterity Therapeutics received FDA End-of-Phase 2 meeting minutes confirming the registrational pathway for ATH434 in Multiple System Atrophy.
Jun 9, 2026, 11:05 UTC
Alterity Therapeutics achieved alignment with the U.S. FDA on the pivotal Phase 3 program for ATH434 in Multiple System Atrophy.